A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆

Annals of Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles